Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new and existing investors Proceeds to advance MC2 receptor antagonist OMS1620 through Phase 2 development and generate early clinical data for SLC15A4 inhibitor Oxford, United Kingdom – 15 October 2026 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company developing small molecule therapeutics against highly validated target ecosystems, today an

iStock, Lari Bat The Gilead Sciences deal, which include $135 million in upfront and near-term payments, marks a critical platform validation for Vir Biotechnology as investors await an upcoming readout in solid tumors. Gilead Sciences has helped bolster the appeal of Vir Biotechnology’s T cell engager technology with a new licensing deal that includes $135 million in upfront and near-term payments—including an equity stake—and could tack on an additional $1.74 billion in milestones. The upfron

Alaunos Therapeutics has bought Velaris Therapeutics, adding four biologics candidates discovered by Paragon Labs targeting pulmonary arterial hypertension (PAH) and related cardiopulmonary diseases. The transaction coincides with Paragon building out its own leadership bench with former executives from Apogee Therapeutics, another company — recently acquired by AbbVie for $10.9 billion — that had been built around Paragon-discovered assets. The Velaris buyout was accompanied by an oversubscribe

Medincell (Euronext Paris: MEDCL) today announced that it has secured an additional €13.8 million in non-dilutive financing from leading European commercial banks and Bpifrance. This additional financing follows the €28 million in non-dilutive bank financing announced in July 2026, bringing the total amount of non-dilutive financing secured since July 2026 to €41.8 million. The financing has been secured on market terms and does not include any equity-linked instruments, resulting in no dilutio

Oct. 14, 2026 -- Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced that the first patient has been dosed in the clinical study of spevatamig for the treatment of colorectal cancer (CRC). Spevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47. It was granted by the FDA orphan drug designation for the treatment of pancreatic cancer in 2022,

Despite the remarkable progress made by ADCs, many cancer patients continue to face disease progression due to treatment resistance, tumor heterogeneity, and dose-limiting toxicities At World ADC 2026 San Diego, Debiopharm presented their latest ADC innovation to overcome these challenges with novel linker-payload technology, including modular dual payload linker MLINK DUO and modular cathepsin B-cleavable linker MLINK Select Research results with various MultiLINKTM Linker Technologies showcas

The US Food and Drug Administration (USFDA) has accepted the Biologics License Application (BLA) for FYB206 for review. To the best of the companies' knowledge, this is the first publicly announced acceptance by the USFDA of a filing for a proposed biosimilar to Keytruda®. FYB206 was developed without a comparative Phase III efficacy trial, following a development pathway agreed upon with the USFDA in early 2025. Zydus holds exclusive commercialization rights for the United States and Canada and

Proof of concept demonstrated for first-in-class oral therapy, addressing multiple aspects of atopic dermatitis pathology and with the potential to deliver lasting benefit to patients SYX-5219 was safe and well-tolerated over the six-week treatment period Clinically meaningful and statistically significant improvements over placebo demonstrated across key measures of atopic dermatitis disease activity including EASI score, PP-NRS (itch score) and vIGA at day 43 Significant correlation of change

Oct. 12, 2026 -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the company to initiate a phase II clinical trial for influenza prevention in general population in the United States. Seasonal vaccination remains central to influenza prevention. However, changes in circulating influenza viruses and va

DTI-117 induced defecation within minutes of intramuscular injection in conscious minipigs, with responder rates rising with dose, and confirmed in a crossover study Pharmacokinetic profile of rapid absorption and fast clearance, with a mean terminal half-life of approximately 3 to 4 minutes, is consistent with a short-acting effect DTI-117 is being evaluated in a NIH-funded randomized, double-blind, placebo-controlled Phase 1 single-ascending-dose study October 13, 2026 – Dignify Therapeutics